Autori: Ana Borovečki, Marijana Braš, Boris Brkljačić, Nina Canki-Klain, Natalija Dedić Plavetić, Blaženka Grahovac, Herman Haller, Nataša Jokić Begić, Iva Kirac, Sonja Levanat, Višnja Matković, Paula Podolski, Ilona Sušac, Mario Šekerija, Ljiljana Šerman, Marina Šprem Goldštajn, Rado Žic, Tamara Žigman
The last few decades have witnessed a great progress in feasibility and clinical utilization of genetic testing for hereditary cancers. Hereditary breast and ovarian cancers are most often the result of BRCA1 and BRCA2 gene mutations. In these guidelines we have covered: the criteria for referral of patients to genetic counselling and testing; the criteria for referral of healthy family members to predictive testing in the event when there is no possibility of testing the patient; the process of genetic counselling before and after testing; test results, their categories and risk levels; recommendations for monitoring of individuals with an increased risk; chemoprevention and prophylactic surgery for carriers of BRCA1 and BRCA2 gene mutations; preservation of reproductive function in women with breast cancer and in carriers of BRCA mutations; and informed consent for genetic testing. The guidelines are intended for all specialists who are in any way involved in the care of patients with hereditary breast and ovarian cancer, and are compiled by the working group according to the data from the relevant medical literature and from clinical experience of the members of the working group.
Broj posjeta: 179